ImmunityBio, Inc.
IBRX
Rang in aandelen
#2232
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Aandeelprijs
$8.55
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$9.06B
Verandering (1 dag)
-6.84%
Verandering (1 jaar)
249.08%
Land
US
Handel ImmunityBio, Inc. (IBRX)
Categorie
Healthcare
Winst voor ImmunityBio, Inc. (IBRX)
Winst in Jun 2026 TTM: $-992.58M
Volgens de meest recente financiële verslagen van ImmunityBio, Inc. bedraagt de huidige winst van het bedrijf $-992.58M. In 2023 behaalde het bedrijf een winst van $-583.89M, een daling ten opzichte van de winst van 2022, die $-417.29M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van ImmunityBio, Inc. van 2013 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-992.58M | 139.96% |
| 2024 | $-413.65M | -29.16% |
| 2023 | $-583.89M | 39.93% |
| 2022 | $-417.29M | 19.28% |
| 2021 | $-349.84M | 54.77% |
| 2020 | $-226.03M | 243.07% |
| 2019 | $-65.89M | -31.89% |
| 2018 | $-96.73M | -0.19% |
| 2017 | $-96.92M | -20.16% |
| 2016 | $-121.38M | -48.82% |
| 2015 | $-237.18M | 3,718.05% |
| 2014 | $-6.21M | 203.62% |
| 2013 | $-2.05M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -631.43% |
US
|
|
| $-3.09B | 211.01% |
US
|
|
| $-4.02B | 304.62% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -296.52% |
NL
|
